Subtype
Esophageal Carcinoma
CI-CAN-00002609ESCAExplore in graph →
307 active trials4 approved drugs11 evidence items
- NCIt
- C3513
- DOID
- 1107
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002609ESCAExplore in graph →
Clinical trials
807 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (62)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07385001 | A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC | recruiting | Phase 1 / Phase 2 | 45 | Tang-Du HospitalOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT05621707 | Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)(RICE) | active not recruiting | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Feb 2, 2026 |
| clinicaltrials |
| NCT07376876 | Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy | not yet recruiting | Phase 2 | 73 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05978193 | Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma(SCR-ESCC-01) | recruiting | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA) | recruiting | Phase 1 / Phase 2 | 117 | Anwaar SaeedOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04229459 | Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. | active not recruiting | Phase 2 | 12 | Baruch BrennerOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04028167 | Induction FLOT With CROSS CRT for Esophageal Cancer | active not recruiting | Phase 2 | 40 | University of Colorado, DenverOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07312578 | Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma | enrolling by invitation | Phase 2 | 48 | Peking UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06161818 | Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction(TNT-OES-2) | recruiting | Phase 2 | 216 | Erasmus Medical CenterOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05342636 | A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) | completed | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Dec 17, 2025 | clinicaltrials |
| NCT07290010 | The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 25 | Hebei Medical University Fourth HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07272291 | A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07266493 | Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 26 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05659251 | Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06576973 | Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04974047 | Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma(RATIONALE-213) | completed | Phase 2 | 70 | BeiGeneINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 19 | CRISPR Therapeutics AGINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07251062 | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 737 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 26, 2025 | clinicaltrials |
| NCT05189730 | Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC(ETNT) | active not recruiting | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06912074 | Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 134 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07086469 | Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05563766 | A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer | recruiting | Phase 2 | 78 | VA Office of Research and DevelopmentFED | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05022654 | SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. | active not recruiting | Phase 2 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07188103 | Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 37 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06601309 | Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC(ESCC) | recruiting | Phase 2 | 90 | Fujian Medical University Union HospitalOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03110926 | Induction Chemotherapy for Locally Advanced Esophageal Cancer | active not recruiting | Phase 2 | 40 | University of RochesterOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07164690 | Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Chemotherapy Combined With Immunotherapy | not yet recruiting | Phase 2 | 32 | Fudan UniversityOTHER | 0 | Sep 10, 2025 | clinicaltrials |
| NCT06247956 | Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer | active not recruiting | Phase 2 | 153 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07152678 | Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma(BRIGHT-ESCC) | recruiting | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06509568 | Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） | recruiting | Phase 2 | 92 | Zhejiang Cancer HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07142421 | A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 35 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT05880082 | PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer(PPIO-004-EC001) | completed | Phase 2 | 118 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07128693 | A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07112833 | A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | not yet recruiting | Phase 2 | 36 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07108855 | Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection(BRIGHT) | recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT03320629 | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 7 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03797625 | Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas | completed | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05173246 | JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma | recruiting | Phase 2 | 43 | Sun Yat-sen UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05834543 | Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 34 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06048913 | Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | completed | Phase 2 | 56 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07049185 | QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma(QICE-ESCC) | not yet recruiting | Phase 2 | 35 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 3, 2025 | clinicaltrials |
| NCT05461794 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 96 | BeiGeneINDUSTRY | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04548440 | Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | completed | Phase 2 | 50 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07016724 | Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer | recruiting | Phase 2 | 208 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06446726 | Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Sichuan UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06988956 | Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 95 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 25, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Feb 3, 2026source: clinicaltrials